Business
Moderna will not commit to previous 2028 breakeven guidance as the ripple effects of the FDA’s refusal-to-file decision spread through its pipeline.
FEATURED STORIES
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company is ready to show the world the science behind the breakthrough.
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Creyon Bio, a drug development company, has launched with more than $40 million in seed and Series A financing led by DCVC Bio and Lux Capital.
According to a BIO report, less than a third of executive team members are women. BioSpace spoke with three influential women in biopharma to get their advice on breaking the executive barrier.
Agenus and Targovax partner on a KRAS cancer vaccine, Elixirgen and Taisho target aging and Tonix and Mass General team up again to fight kidney transplant rejection.
Andrey Tolmachov issued a letter to the global drug discovery and scientific community, underscoring the importance of condemnation and action against Russian invasion.
China has become a leader in biotech in the last five years, especially in CAR-T therapies. Companies like Johnson & Johnson are on the prowl to acquire Chinese companies to form collaborations.
Three biotech firms announced a change in leadership recently, led by Pardes Biosciences, followed by HUTCHMED and BeiGene. Read the details below.
The Phase I study could potentially result in RP-A501 becoming the first gene therapy for monogenic heart failure.
Robert Califf became the new commissioner of the U.S. Food & Drug Administration and emphasized the use of real-world evidence (RWE) in Agency decisions.
With all of this innovation coming down the pike, Gallant shared that Daiichi Sankyo is currently in growth mode, particularly when it comes to oncology.
As COVID-19 cases fall in the wake of the latest surge from the Omicron variant, the question on the minds of many is, what comes next for these Pfizer and Moderna?